Animal Models in the Evaluation of the Effectiveness of Phage Therapy for Infections Caused by Gram-Negative Bacteria from the ESKAPE Group and the Reliability of Its Use in Humans

Overview

Journal Microorganisms

Specialty Microbiology

Date 2021 Jan 27

PMID 33498243

Citations 20

Authors

Martyna Cieslik

Natalia Baginska

Andrzej Gorski

Ewa Jonczyk-Matysiak

Affiliations

Soon will be listed here.

Abstract

The authors emphasize how extremely important it is to highlight the role played by animal models in an attempt to determine possible phage interactions with the organism into which it was introduced as well as to determine the safety and effectiveness of phage therapy in vivo taking into account the individual conditions of a given organism and its physiology. Animal models in which phages are used make it possible, among other things, to evaluate the effective therapeutic dose and to choose the possible route of phage administration depending on the type of infection developed. These results cannot be applied in detail to the human body, but the knowledge gained from animal experiments is invaluable and very helpful. We would like to highlight how useful animal models may be for the possible effectiveness evaluation of phage therapy in the case of infections caused by gram-negative bacteria from the ESKAPE (, , , , , species) group of pathogens. In this review, we focus specifically on the data from the last few years.

Citing Articles

Mucosal-adapted bacteriophages as a preventive strategy for a lethal Pseudomonas aeruginosa challenge in mice.

Coelho L, de Souza Terceti M, Neto S, Amaral R, Dos Santos A, Gozzi W Commun Biol. 2025; 8(1):13.

PMID: 39762450 PMC: 11704353. DOI: 10.1038/s42003-024-07269-0.

Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.

Siopi M, Skliros D, Paranos P, Koumasi N, Flemetakis E, Pournaras S Clin Microbiol Rev. 2024; 37(3):e0004424.

PMID: 39072666 PMC: 11391690. DOI: 10.1128/cmr.00044-24.

Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.

Yu H, Xu Y, Imani S, Zhao Z, Ullah S, Wang Q ACS Infect Dis. 2024; 10(7):2336-2355.

PMID: 38866389 PMC: 11249778. DOI: 10.1021/acsinfecdis.4c00007.

Disrupting quorum sensing as a strategy to inhibit bacterial virulence in human, animal, and plant pathogens.

Gonzales M, Kergaravat B, Jacquet P, Billot R, Grizard D, Chabriere E Pathog Dis. 2024; 82.

PMID: 38724459 PMC: 11110857. DOI: 10.1093/femspd/ftae009.

Controlling the bacterial load of Salmonella Typhi in an experimental mouse model by a lytic Salmonella phage STWB21: a phage therapy approach.

Mondal P, Halder P, Mallick B, Bhaumik S, Koley H, Dutta S BMC Microbiol. 2023; 23(1):324.

PMID: 37924001 PMC: 10623789. DOI: 10.1186/s12866-023-03040-3.

References

Vazquez R, Garcia E, Garcia P . Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Front Immunol. 2018; 9:2252. PMC: 6232686. DOI: 10.3389/fimmu.2018.02252. View

Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T . Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One. 2012; 7(10):e47742. PMC: 3474789. DOI: 10.1371/journal.pone.0047742. View

Davin-Regli A, Lavigne J, Pages J . spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. Clin Microbiol Rev. 2019; 32(4). PMC: 6750132. DOI: 10.1128/CMR.00002-19. View

Wintachai P, Naknaen A, Thammaphet J, Pomwised R, Phaonakrop N, Roytrakul S . Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo. Sci Rep. 2020; 10(1):11803. PMC: 7367294. DOI: 10.1038/s41598-020-68702-y. View

Britt N, Ritchie D, Kollef M, Burnham C, Durkin M, Hampton N . Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrob Agents Chemother. 2018; 62(4). PMC: 5913923. DOI: 10.1128/AAC.02400-17. View

Santajit S, Indrawattana N . Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016; 2016:2475067. PMC: 4871955. DOI: 10.1155/2016/2475067. View

Ayoub Moubareck C, Hammoudi Halat D . Insights into : A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics (Basel). 2020; 9(3). PMC: 7148516. DOI: 10.3390/antibiotics9030119. View

Santaniello A, Sansone M, Fioretti A, Menna L . Systematic Review and Meta-Analysis of the Occurrence of ESKAPE Bacteria Group in Dogs, and the Related Zoonotic Risk in Animal-Assisted Therapy, and in Animal-Assisted Activity in the Health Context. Int J Environ Res Public Health. 2020; 17(9). PMC: 7246456. DOI: 10.3390/ijerph17093278. View

Djordjevic Z, Folic M, Zivic Z, Markovic V, Jankovic S . Nosocomial urinary tract infections caused by Pseudomonas aeruginosa and Acinetobacter species: sensitivity to antibiotics and risk factors. Am J Infect Control. 2013; 41(12):1182-7. DOI: 10.1016/j.ajic.2013.02.018. View

10.

Nilsson A . Pharmacological limitations of phage therapy. Ups J Med Sci. 2019; 124(4):218-227. PMC: 6968538. DOI: 10.1080/03009734.2019.1688433. View

11.

BENNETT Jr I, Beeson P . Studies on the pathogenesis of fever. I. The effect of injection of extracts and suspensions of uninfected rabbit tissues upon the body temperature of normal rabbits. J Exp Med. 1953; 98(5):477-92. PMC: 2136326. DOI: 10.1084/jem.98.5.477. View

12.

Basu S, Agarwal M, Bhartiya S, Nath G, Shukla V . An In vivo Wound Model Utilizing Bacteriophage Therapy of Pseudomonas aeruginosa Biofilms. Ostomy Wound Manage. 2015; 61(8):16-23. View

13.

Jeon J, Yong D . Two Novel Bacteriophages Improve Survival in Infection and Mouse Acute Pneumonia Models Infected with Extensively Drug-Resistant . Appl Environ Microbiol. 2019; 85(9). PMC: 6495756. DOI: 10.1128/AEM.02900-18. View

14.

Fischetti V . Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol. 2010; 300(6):357-62. PMC: 3666336. DOI: 10.1016/j.ijmm.2010.04.002. View

15.

Otero J, Garcia-Rodriguez A, Cano-Sarabia M, Maspoch D, Marcos R, Cortes P . Biodistribution of Liposome-Encapsulated Bacteriophages and Their Transcytosis During Oral Phage Therapy. Front Microbiol. 2019; 10:689. PMC: 6458305. DOI: 10.3389/fmicb.2019.00689. View

16.

Iversen C, Lehner A, Mullane N, Bidlas E, Cleenwerck I, Marugg J . The taxonomy of Enterobacter sakazakii: proposal of a new genus Cronobacter gen. nov. and descriptions of Cronobacter sakazakii comb. nov. Cronobacter sakazakii subsp. sakazakii, comb. nov., Cronobacter sakazakii subsp. malonaticus subsp. nov.,.... BMC Evol Biol. 2007; 7:64. PMC: 1868726. DOI: 10.1186/1471-2148-7-64. View

17.

Lee C, Lee J, Park K, Kim Y, Jeong B, Lee S . Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front Microbiol. 2016; 7:895. PMC: 4904035. DOI: 10.3389/fmicb.2016.00895. View

18.

Pang W, Song J, Lu Y, Zhang X, Zheng H, Jiang J . Host Restriction Factors APOBEC3G/3F and Other Interferon-Related Gene Expressions Affect Early HIV-1 Infection in Northern Pig-Tailed Macaque (). Front Immunol. 2018; 9:1965. PMC: 6120991. DOI: 10.3389/fimmu.2018.01965. View

19.

Nordmann P, Cuzon G, Naas T . The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9(4):228-36. DOI: 10.1016/S1473-3099(09)70054-4. View

20.

Chang R, Wong J, Mathai A, Morales S, Kutter E, Britton W . Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. Eur J Pharm Biopharm. 2017; 121:1-13. PMC: 5650506. DOI: 10.1016/j.ejpb.2017.09.002. View